![SonomaEye-full-color-vector[2].png](https://static.wixstatic.com/media/bed00b_da20b9cc704044b0b048ac8ef9190470~mv2_d_3024_2195_s_2.png/v1/fill/w_177,h_123,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/SonomaEye-full-color-vector%5B2%5D.png)
Retina 2
Saturday, 3/18/2023
10:00 am - 11:30 am
Moderators: Diana V. Do, MD and David Boyer, MD
10:00 am – 10:10 am: Photobiomodulation for Age-Related Macular Degeneration: Outcomes of the LIGHTSITE III Study (First Time for Results to Be Presented) (Diana V. Do, MD)
10:10 am – 10:20 am: Update on Pegcetacoplan for Geographic Atrophy: The DERBY and OAKS Phase 3 Trials (David Boyer, MD)
10:20 am – 10:30 am: Treatment Response to Avacincaptad Pegol by Patient Baseline Characteristics: A Prespecified Subgroup Analysis of the Phase 3 GATHER2 Study (Michael Ip, MD)
10:30 am – 10:40 am: Update on Faricimab for AMD and DME (Diana V. Do, MD)
10:40 am – 10:50 am: Hi-Dose Aflibercept for DME: The PHOTON Study (David Boyer, MD)
10:50 am – 11:00 am: The HORNBILL Study: A Phase I/IIa Trial Examining BI-X in Patients with Diabetic Macular Ischemia (Sobha Sivaprasad, MBBS, MS, DM, FRCS, FRCOphth)
11:00 am – 11:10 am: Are Biosimilars the Bio-Same? (Rajiv Shah, MD)
11:10 am – 11:20 am: Intraocular Inflammation in the Setting of Ocular Gene Therapy: Management and Pearls (David Almeida, MD, MBA, PhD)
11:20 am – 11:30 am: Panel Discussion: Managing Retinal Vascular Diseases with Protean Therapeutic Options
Moderator: Diana V. Do, MD
Panelists: Rajat Agrawal, MD, MS, David Almeida, MD, David Boyer, MD, Michael Ip, MD, Rajiv Shah, MD, Sobha Sivaprasad, MBBS, MS, DM, FRCS, FRCOphth